Bullous Pemphigoid: Diagnosis and Management

Overview / Definition Bullous pemphigoid (BP) is a chronic autoimmune skin disorder that leads to the formation of tense blisters on normal or erythematous skin. It occurs due to the autoantibody-mediated subepithelial separation at the basement membrane zone, primarily targeting the hemidesmosomal proteins BP180 and BP230. Epidemiology Bullous pemphigoid is predominantly seen in the elderly population, with an incidence of approximately 1.5 to 3.5 cases per 100,000 individuals annually. The condition is more common in individuals aged over 60 years, with a slight female predominance. Age of onset: Typically >60 years Gender: Slightly more prevalent in females Geographic variation: More common in Europe than in Asia Pathophysiology / Mechanism The pathogenesis of bullous pemphigoid involves the formation of autoantibodies against components of the basement membrane zone, particularly: BP180 (collagen XVII): A transmembrane protein crucial for epidermal adhesion. BP230: A cytoplasmic protein associated with hemidesmosomes. These autoantibodies lead to an inflammatory response, activating complement and resulting in the recruitment of eosinophils and other inflammatory cells, ultimately causing subepithelial blister formation. Clinical Presentation Patients with bullous pemphigoid typically present with: Tense blisters: Usually located on the abdomen, groin, and extremities. Pruritus: Severe itching often precedes blister formation. Lesion appearance: Blisters are often surrounded by erythematous skin. The disease can be localized or generalized, and blisters may be mistaken for other dermatological conditions, such as contact dermatitis or dermatitis herpetiformis. Diagnosis / Workup The diagnosis of bullous pemphigoid involves a combination of clinical evaluation and laboratory testing: Clinical history: Detailed history of symptoms and onset. Direct immunofluorescence (DIF): Skin biopsy from the edge of a blister shows linear deposition of IgG and complement compon